Lawrenceville, NJ, USA—October 23, 2018—Value in Health, the official journal of ISPOR (the professional society for health economics and outcomes research), announced today the publication of new research showing that Medicare Part D prescription plans with higher generic drug use have higher summary star ratings and improved member experience. The report, Association Between Higher Generic Drug Use and Medicare Part D Star Ratings: An Observational Analysis was published in the October 2018 issue of Value in Health.
A research team from Auburn University and IMPAQ International conducted a retrospective, observational study using 2011 Medicare contract-level prescription, rating, and enrollment data. A total of 477 individual Medicare prescription contracts were included, representing 75% of total Prescription Drug Plans and more than 65% of total Medicare Advantage Prescription Drug Plans available by the end of 2010. Results indicate that Medicare Part D prescription plans with a higher proportion of generic drugs dispensed received both higher summary star ratings and higher “member experience with drug plan” ratings.
“These findings support our hypothesis that increased dispensing of generic drugs compared with brand drugs may be associated with improved Medicare Part D prescription plan summary star ratings,” said author Natalie Hohmann, PharmD, Department of Health Outcomes Research and Policy, Auburn University Harrison School of Pharmacy, Auburn, Alabama, USA. “This knowledge is useful in making informed decisions regarding the role of generic drug use in improving quality ratings for Medicare Part D prescription plans. In turn, this may afford Medicare beneficiaries with improved access to high-quality prescription plans and lower cost medications, thereby improving beneficiary satisfaction and quality of care. Consideration may be given to incorporating proportion of generic drugs dispensed into Medicare Part D star rating measures to improve quality of prescription plans.”
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg
ABOUT VALUE IN HEALTH
Value in Health (ISSN 1098-3015) is an international, indexed journal that publishes original research and health policy articles that advance the field of health economics and outcomes research to help healthcare leaders make evidence-based decisions. The journal’s 2017 impact factor score is 5.494. Value in Health is ranked 3rd among 94 journals in healthcare sciences and services, 3rd among 79 journals in health policy and services, and 6th among 353 journals in economics. Value in Health is a monthly publication that circulates to more than 10,000 readers around the world.
Web: www.ispor.org/valueinhealth_index.asp | Twitter: www.twitter.com/ISPORJournals (@ISPORjournals)